ARVCF

ARVCF is an armadillo-repeat catenin that functions as a dual-compartment regulator of cell adhesion, Rho GTPase signaling, and pre-mRNA processing. At adherens junctions, its armadillo repeats bind the juxtamembrane domain of classical cadherins (E-, N-, M-, VE-cadherin), competing with p120-catenin for this site, while its C-terminal PDZ-binding motif recruits scaffolding proteins ZO-1, ZO-2, and Erbin to stabilize junctional complexes; loss of ARVCF destabilizes cadherin nanoclusters, impairs endothelial barrier function, and causes age-related cortical cataracts in mice (PMID:10725230, PMID:11058098, PMID:11821434, PMID:15456900, PMID:35874813, PMID:42006337). Upon disruption of cell–cell contacts, ARVCF translocates to the nucleus—partly via ZO-2—where it interacts with splicing factors SRSF1, DDX5, and hnRNP H2 to regulate alternative pre-mRNA splicing, acting downstream of p53 to mediate apoptosis and modulating RRAGA 3′ UTR processing to suppress mTOR signaling (PMID:24644279, PMID:31827232, PMID:41058879). In developing embryos, ARVCF suppresses RhoA and activates Rac through a complex containing KazrinA and p190B RhoGAP, and its depletion disrupts gastrulation, convergent extension, and cranial neural crest migration, phenotypes relevant to 22q11.2 deletion syndrome (PMID:15067024, PMID:21062899, PMID:22028109, PMID:35476939).

1. 1997 Medium

   The discovery of ARVCF as a new p120-related armadillo-repeat protein within the 22q11 deletion region established it as a candidate gene for velo-cardio-facial/DiGeorge syndrome and predicted a role in cadherin-based adhesion.

   Evidence Gene isolation and domain analysis from the 22q11 critical region

   PMID:9126485

   Open questions at the time

   • No binding partners or functional data yet obtained
   • Relationship to p120ctn at cadherins untested
2. 2000 High

   Demonstration that ARVCF binds the cadherin juxtamembrane domain via its armadillo repeats and competes with p120-catenin resolved how two related catenins share the same binding site and revealed that ARVCF, unlike p120, also localizes to the nucleus.

   Evidence Reciprocal co-IP, competition assays, chimeric protein domain mapping in mammalian cells; yeast two-hybrid and MOM recruitment assays with M-cadherin

   PMID:10725230 PMID:11058098

   Open questions at the time

   • Nuclear function of ARVCF unknown
   • Mechanism determining which catenin occupies cadherin not resolved
3. 2002 High

   Identification of Erbin as a high-affinity PDZ-domain partner of ARVCF's C-terminal motif showed that ARVCF recruits additional scaffolding proteins to the cadherin–catenin complex, extending junction composition beyond classical catenins.

   Evidence Phage display, synthetic peptide binding, co-IP, mutagenesis, and peptide competition

   PMID:11821434

   Open questions at the time

   • Functional consequence of Erbin recruitment to junctions not tested
   • Whether ZO proteins also use this motif not yet examined
4. 2004 High

   Discovery that ZO-1 and ZO-2 bind ARVCF's PDZ-binding motif and that adhesion disruption releases ARVCF to the nucleus (partly via ZO-2) established a signaling mechanism by which junctional status controls ARVCF nuclear translocation.

   Evidence Reciprocal co-IP, deletion constructs, adhesion disruption assays in MDCK cells

   PMID:15456900

   Open questions at the time

   • Nuclear targets and transcriptional or RNA-processing functions not yet identified
   • Relative contributions of ZO-1 vs ZO-2 to ARVCF localization unclear
5. 2004 High

   Epistasis experiments in Xenopus embryos placed ARVCF functionally upstream of RhoA/Rac GTPase signaling during gastrulation, showing that ARVCF and p120ctn are interchangeable in regulating cell movements essential for body axis formation.

   Evidence Morpholino knockdown with self- and cross-rescue, dominant-negative RhoA and dominant-active Rac rescue in Xenopus

   PMID:15067024

   Open questions at the time

   • Direct biochemical mechanism linking ARVCF to GTPase regulation not identified
   • Whether ARVCF acts through a RhoGAP unknown
6. 2010 High

   Biochemical resolution of an ARVCF–KazrinA–β2-spectrin ternary complex and demonstration that Kazrin depletion phenotypes are rescued by ARVCF identified the molecular pathway through which ARVCF suppresses RhoA via p190B RhoGAP to maintain epithelial integrity.

   Evidence Co-IP, pulldown, ternary complex biochemistry, morpholino knockdown with rescue and RhoA activity assays in Xenopus

   PMID:21062899

   Open questions at the time

   • Whether this complex operates in mammalian epithelia not shown
   • Structural basis of ARVCF–KazrinA interaction unresolved
7. 2011 Medium

   ARVCF depletion in Xenopus impaired cranial neural crest migration and craniofacial skeleton formation, and cooperative defects with Tbx1 co-depletion linked ARVCF to 22q11.2 deletion syndrome-associated developmental phenotypes.

   Evidence Morpholino knockdown, double-knockdown epistasis, and molecular marker analysis in Xenopus

   PMID:22028074 PMID:22028109

   Open questions at the time

   • No mammalian neural crest data
   • Molecular mechanism downstream of ARVCF in neural crest cells undefined
8. 2014 High

   Identification of nuclear ARVCF as an RNA-independent interactor of splicing factors SRSF1, DDX5, and hnRNP H2, combined with transcriptome-wide splicing changes upon ARVCF depletion, established a second major function for ARVCF as a regulator of alternative pre-mRNA splicing.

   Evidence Co-IP with domain mapping, RNA-seq after ARVCF knockdown, reporter splicing assays

   PMID:24644279

   Open questions at the time

   • How ARVCF modulates splicing factor activity mechanistically unknown
   • Which splicing targets are physiologically critical not determined
9. 2019 Medium

   ChIP-seq identification of ARVCF as a direct p53 transcriptional target, together with the requirement for ARVCF in p53-induced apoptosis mediated through splicing regulation, connected ARVCF's nuclear RNA-processing function to tumor suppression.

   Evidence ChIP-seq for p53, siRNA knockdown, apoptosis assays, co-IP with hnRNPH2, splicing analysis

   PMID:31827232

   Open questions at the time

   • Identity of critical pro-apoptotic splice variants regulated by ARVCF unknown
   • Whether ARVCF loss contributes to tumorigenesis in vivo untested
10. 2022 High

    Conditional knockout of Arvcf in mouse lens demonstrated its requirement for N-cadherin nanocluster stability and fiber cell organization, providing the first mammalian genetic evidence that ARVCF maintains cadherin complex integrity in vivo, with loss causing cortical cataracts.

    Evidence Conditional knockout mice, super-resolution imaging, electron microscopy, biomechanics

    PMID:35874813

    Open questions at the time

    • Whether cataract phenotype is p120-independent not addressed
    • Systemic phenotypes of global Arvcf KO in mice not fully characterized
11. 2022 Medium

    Live imaging in Xenopus showed that Arvcf is required for pulsatile recruitment of adhesion and cytoskeletal proteins to cell membranes during convergent extension, linking molecular-scale adhesion dynamics to tissue-scale force generation.

    Evidence Morpholino knockdown, live imaging of membrane protein dynamics, tissue force measurements in Xenopus

    PMID:35476939

    Open questions at the time

    • Mechanism by which ARVCF controls pulsatile recruitment unclear
    • Whether this reflects RhoA/Rac regulation or a distinct pathway untested
12. 2025 High

    Mass spectrometry-based interactomics in endothelial cells revealed that ARVCF selectively binds a p120-free pool of VE-cadherin through its C-terminal disordered regions, and its depletion destabilizes junctions and impairs barrier function, extending the competitive catenin model to the endothelium.

    Evidence MS interactomics, reciprocal co-IP, siRNA depletion with barrier and migration assays

    PMID:42006337

    Open questions at the time

    • Whether ARVCF's disordered region contacts VE-cadherin directly or via an intermediary not resolved
    • In vivo vascular phenotype not tested
13. 2025 Medium

    Arvcf knockout mice showed reduced dopamine synthesis and release in the VTA–NAc circuit and attenuated nicotine reward, revealing a previously unsuspected neuronal function for ARVCF in dopaminergic neurotransmission.

    Evidence Arvcf-KO mice, conditioned place preference, snRNA-seq, dopamine measurements, viral manipulation in VTA

    PMID:40082601

    Open questions at the time

    • Molecular mechanism linking ARVCF to dopamine synthesis or vesicle release unknown
    • Whether this reflects a junctional, splicing, or novel function not determined
14. 2025 Medium

    A VIM–ARVCF–RRAGA–mTOR axis was defined in which ARVCF maintains RRAGA 3′ UTR length via alternative polyadenylation, suppressing mTOR–EIF4G1 signaling; ARVCF overexpression rescued VIM-KO-induced mTOR activation in lymphoma cells, linking ARVCF's RNA-processing function to oncogenic signaling.

    Evidence RNA-seq, APA analysis, proteomics, ARVCF overexpression rescue, proliferation assays in B cell lymphoma

    PMID:41058879

    Open questions at the time

    • Whether ARVCF directly regulates polyadenylation or acts via splicing factors not distinguished
    • In vivo relevance in lymphomagenesis untested

• Key open questions include the structural basis for ARVCF's selectivity among cadherins and competition with p120-catenin, the precise mechanism by which ARVCF modulates splicing factor activity in the nucleus, how its junctional and nuclear functions are coordinately regulated in different tissues, and the molecular pathway through which ARVCF controls dopamine synthesis in VTA neurons.
• No crystal/cryo-EM structure of ARVCF–cadherin or ARVCF–splicing factor complexes
• Tissue-specific balance between junctional and nuclear pools not quantified
• Mechanism linking ARVCF to dopamine biosynthesis entirely unknown